Short answer
Spyre Therapeutics, Inc. (SYRE) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$96M
- −759.5% YoY · −165.5% QoQ
- EPS (diluted)
- −$0.95
- −533.3% YoY · −171.4% QoQ
Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) Q3 2026 10-Q on SEC EDGAR. USD.
Spyre Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no commercial product sales
- Net loss $96.1M vs $11.2M YoY, operating loss $105.7M vs $56.9M
- Gastroenterology largest R&D program at $38.3M, dermatology fastest-growing at $11.9M vs $0
- Operating cash outflow $204.7M, financing inflow $446.9M, including $435.2M April offering proceeds
- Funding outlook: resources expected through second half of 2029, additional financing needed for further development
Risk Factors
- Newly added risk: BIOSECURE Act could force CMO changes, triggered by FY 2026 National Defense Authorization Act restrictions on Chinese biotechnology companies
- Most materially updated risk: SPY072 rheumatic-disease program discontinued in November 2026 after Phase 2 development
- Regulatory risk: FDA disruptions from federal layoffs, leadership turnover, budget pressure, and potential shutdowns could delay submissions
- Operational risk: WuXi Biologics remains a China-based CMO, creating potential manufacturing-transfer delays if designated a biotechnology company of concern
- Financial risk: $1.1 billion cash, cash equivalents, and marketable securities as of September 30, 2026, but continued capital raises may dilute stockholders
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spyre Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.